Literature DB >> 11695099

[Revised CBO guideline 'Follow-up after polypectomy'].

F M Nagengast1, C J Kaandorp.   

Abstract

The purpose of follow-up after polypectomy of one or more colorectal adenomatous polyps, is the timely removal of new adenomas and thereby the prevention of colorectal cancer. The first check-up following index-polypectomy can be carried out after six years if one or two adenomas were encountered during the index polypectomy, and after three years if three or more adenomas were encountered. The same check-up interval of six and three years respectively applies if none to two or more than three adenomas are encountered when a check-up colonoscopy is carried out. A check-up one year after the polypectomy and check-ups more frequently than respectively six and three years after polypectomy are not considered to be useful, while each check-up is accompanied by risks and costs. Check-ups can be suspended for patients in whom cumulatively one adenomatous polyp has been removed: from the age of 65 years, for patients in whom cumulatively two adenomas have been removed: from the age of 75 years, and for patients in whom cumulatively three adenomas have been removed check-ups must be continued for as long as the patient's vitality justifies this. Also if no adenomas are encountered during three consecutive check-ups, a suspension of the check-ups can be considered. Separate guidelines apply to patients with genetically determined adenomas.

Entities:  

Mesh:

Year:  2001        PMID: 11695099

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  7 in total

1.  Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.

Authors:  Iris Lansdorp-Vogelaar; S Lucas Goede; Linda J W Bosch; Veerle Melotte; Beatriz Carvalho; Manon van Engeland; Gerrit A Meijer; Harry J de Koning; Marjolein van Ballegooijen
Journal:  Clin Gastroenterol Hepatol       Date:  2017-07-18       Impact factor: 11.382

2.  Study protocol: population screening for colorectal cancer by colonoscopy or CT colonography: a randomized controlled trial.

Authors:  Thomas R de Wijkerslooth; Margriet C de Haan; Esther M Stoop; Marije Deutekom; Paul Fockens; Patrick M M Bossuyt; Maarten Thomeer; Marjolein van Ballegooijen; Marie-Louise Essink-Bot; Monique E van Leerdam; Ernst J Kuipers; Evelien Dekker; Jaap Stoker
Journal:  BMC Gastroenterol       Date:  2010-05-19       Impact factor: 3.067

3.  Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening.

Authors:  S Lucas Goede; Aafke H C van Roon; Jacqueline C I Y Reijerink; Anneke J van Vuuren; Iris Lansdorp-Vogelaar; J Dik F Habbema; Ernst J Kuipers; Monique E van Leerdam; Marjolein van Ballegooijen
Journal:  Gut       Date:  2012-04-05       Impact factor: 23.059

4.  Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round.

Authors:  Inge Stegeman; Thomas R de Wijkerslooth; Rosalie C Mallant-Hent; Karin de Groot; An K Stroobants; Paul Fockens; Marco Mundt; Patrick Mm Bossuyt; Evelien Dekker
Journal:  BMC Gastroenterol       Date:  2012-06-19       Impact factor: 3.067

5.  Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study.

Authors:  Else-Mariëtte B van Heijningen; Iris Lansdorp-Vogelaar; Ewout W Steyerberg; S Lucas Goede; Evelien Dekker; Wilco Lesterhuis; Frank ter Borg; Juda Vecht; Pieter Spoelstra; Leopold Engels; Clemens J M Bolwerk; Robin Timmer; Jan H Kleibeuker; Jan J Koornstra; Harry J de Koning; Ernst J Kuipers; Marjolein van Ballegooijen
Journal:  Gut       Date:  2015-01-13       Impact factor: 23.059

6.  Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands.

Authors:  Maaike J Denters; Marije Deutekom; Paul Fockens; Patrick M M Bossuyt; Evelien Dekker
Journal:  BMC Gastroenterol       Date:  2009-04-24       Impact factor: 3.067

7.  Metachronous neoplasms in patients with laterally spreading tumours during surveillance.

Authors:  Roel M M Bogie; Bjorn Winkens; Sean J J Retra; Chantal M C le Clercq; Mariëlle W Bouwens; Eveline J A Rondagh; Li-Chun Chang; Rogier de Ridder; Chantal Hoge; Jan-Willem Straathof; Danny Goudkade; Silvia Sanduleanu-Dascalescu; Ad A M Masclee
Journal:  United European Gastroenterol J       Date:  2021-02-18       Impact factor: 4.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.